OncLive TV

Charles E. Geyer, MD, discusses ILD and radiation pneumonitis incidence by radiotherapy timing with T-DXd in a DESTINY-Breast05 safety analysis.

Uma Borate, MBBS, MS, discusses results of the OPTI-AML trial comparing 14- and 28-day venetoclax dosing in older adults with acute myeloid leukemia.

Kim A. Reiss Binder, MD, notes the significance of the approval of daraxonrasib for metastatic PDAC and how it positions a new era for RAS-targeted drugs.

Adanma Ayanambakkam, MD, MS, discusses safety data with darlifarnib plus cabozantinib in RCC.

Daniel Morillo, MD, discusses future research directions for golcadomide in relapsed/refractory follicular lymphoma.

Zulfa Omer, MD, discusses BTK degraders, how they differentiate from BTK inhibitors, and their remaining unknowns for chronic lymphocytic leukemia.

Adanma Ayanambakkam, MD, MS, discusses the design of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.

Zev A. Wainberg, MD, discusses the mechanism of action of zanidatamab and its FDA approval as a new frontline option for HER2-positive gastric cancer.

Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.

Adanma Ayanambakkam, MD, MS, discusses the background of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.

Meredith Pelster, MD, MSCI, discusses phase 2a data for atebimetinib plus chemotherapy and the design of a phase 2 trial in pancreatic cancer.

Zev A. Wainberg, MD, discusses early-phase INCB161734 data in refractory pancreatic cancer and the evolving RAS inhibitor landscape.

Paul E. Oberstein, MD, discusses a personalized mRNA vaccine being evaluated in pancreatic ductal adenocarcinoma and why it matters.

Daniel Morillo, MD, discusses AEs associated with golcadomide plus rituximab in relapsed/refractory follicular lymphoma.

Daniel Morillo, MD, discusses efficacy data for golcadomide plus rituximab in relapsed/refractory follicular lymphoma.

Javier Cortés, MD, PhD, discusses the design of the ASPEN-09-03 trial and the development of CD47 as a biomarker in pretreated HER2-positive breast cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses first-line efficacy data for divarasib plus pembrolizumab in KRAS G12C+ NSCLC from the KRASCENDO-170 study.

Madhur K. Garg, MD, MBA, MBBS, discusses the safety of proton therapy in patients with head and neck cancer.

Sara A. Hurvitz, MD, FACP, discusses the SERENA-6 data and the case for an early ctDNA-guided switch to camizestrant in HR-positive breast cancer.

Daniel Morillo, MD, discusses the mechanism of action of golcadomide as a potential treatment for relapsed/refractory follicular lymphoma.

Alexandra Leary, MD, PhD, discusses PFS and safety data from the phase 2 TEDOVA trial of Tedopi plus pembrolizumab in platinum-sensitive ovarian cancer.

Alessandro A. Viansone, MD, discusses the SATEEN study, ADC-after-ADC sequencing, and maintaining HER2 selective pressure in metastatic breast cancer.

Alessandro A. Viansone, MD, discusses balancing ADCs such as T-DXd against low-toxicity chemotherapy in HER2-positive breast cancer therapy de-escalation.

Michael J. Morris, MD, discusses key ongoing clinical trials in prostate cancer.

Alessandro A. Viansone, MD, discusses data that support chemotherapy de-escalation in HER2-positive breast cancer.

Shailender Bhatia, MD, discusses phase 3 ADAM trial data on relapse-free survival and safety with adjuvant avelumab in Merkel cell carcinoma.

Matteo S. Carlino, MBBS, PhD, FRACP, discusses how neoantigen-specific T cells link to intismeran autogene’s KEYNOTE-942 recurrence benefit.

Estelamari Rodriguez, MD, MPH, discusses the rationale for combining LAG-3 and PD-1 blockade to overcome immunotherapy resistance in NSCLC.

Rahul Banerjee, MD, FACP, discusses the FDA accelerated approval of iberdomide plus daratumumab/dexamethasone in relapsed/refractory myeloma.

Madhur K. Garg, MD, MBA, MBBS, discusses findings from a phase 3 study of proton therapy in patients with head and neck cancer.